Inhibitors of UDP-galactopyranose mutase
Compounds and salts thereof which are acyl-sulfonamides or certain carboxylic acids and which inhibit microbial growth or attenuate the virulence of pathogenic microorganisms and which inhibit UDP-galactopyranose mutase (UGM). Compounds of the invention include 2-aminothiazoles and triazolothiadiazines, particularly 3,6,7-substituted-7H-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazines, and 2-amino and salts thereof. Methods for inhibiting growth or attenuating virulence of microbial pathogens including mycobacterium , for example, M. tuberculosis and M. smegmatis and Klebsiella , for example, Klebsiella pneumoniae . Methods for inhibiting eukaryotic human and animal pathogens, and fungi and nematodes in particular. Methods for treatment of infections by prokaryotic and eukaryotic pathogens employing compounds of the invention.
1. A compound of formula I:
or salts thereof,
wherein
n is 0 or 1 and L is —(CH 2 ) q - or O—(CH 2 ) q , where q is 1, 2 or 3;
m is 0, 1, 2, or 3;
R is an optionally substituted C 1 -C 6 alkyl, an optionally substituted C 1 -C 6 alkenyl, an optionally substituted alkoxy, an optionally substituted thioalkyl, an optionally substituted carbocyclyl, or an optionally substituted heterocyclyl;
R 1 and R 2 are independently selected from optionally substituted carbocyclyl, and optionally substituted heterocyclyl; and
wherein optional substitution is substitution by one or more non-hydrogen substituents selected from halogen, hydroxyl, mercapto, nitro, cyano, azide, isocyano, thiocyano, oxo, optionally substituted C 1 -C 3 alkyl, optionally substituted C 1 -C 3 -alkenyl, optionally substituted C 1 -C 3 alkoxy, acyl, halogenated phenyl, nitrophenyl, alkoxyphenyl, thioalkyl, optionally substituted heteroaryl, optionally substituted cycloalkyl, optionally substituted heterocyclyl, —SO 2 —N(R S ) 2 , —SO 2 —R S , —COOR S , —COR S , —CON(R S ) 2 , —N(R S ) 2 , where R S is hydrogen, C 1 -C 3 alkyl, C 1 -C 3 alkenyl, C 1 -C 3 haloalkyl, C 1 -C 3 haloalkoxy, phosphate, phosphonate, or carboxyl.
2. The compound of claim 1 , wherein R 1 and R 2 are independently selected from phenyl, biphenyl, naphthyl or heteroaryl, wherein each of these groups are optionally substituted with one or more halogen, nitro, cyano, C 1 -C 3 alkyl, C 1 -C 3 alkoxy, acyl, or C 1 -C 3 haloalkyl.
3. The compound of claim 1 , wherein R 1 and R 2 are independently selected from phenyl, biphenyl, or heteroaryl, wherein each of these groups are optionally substituted with one or more halogen, nitro, methyl, methoxy, acetyl or trifluoromethyl.
4. The compound of claim 1 , wherein R 1 and R 2 are different groups.
5. The compound of claim 1 , wherein one of R 1 and R 2 is selected from optionally substituted biphenyl, or optionally substituted naphthyl and the other of R 1 or R 2 is selected from optionally substituted phenyl or optionally substituted heteroaryl, wherein optionally substituted is substitution with one or more halogen, nitro, methyl, methoxy, acetyl or trifluormethyl groups.
6. The compound of claim 1 , wherein n is 0 or 1 and m is 0 or 1.
7. The compound of claim 1 , wherein R 1 is 4-bromo phenyl, 4-iodo phenyl, naphthyl, or biphenyl and R 2 is 4-bromophenyl, 4-iodo phenyl, 4-chlorophenyl, 3,4-dichlorophenyl or biphenyl.
8. A method for inhibiting Uridine 5′-diphosphate (UDP)-galactopyranose mutase (UGM) which comprises contacting UGM with an amount of one or more compounds or salts of claim 1 effective for inhibiting the enzyme.
9. The method of claim 8 , wherein the UGM is that of a mycobacterium or a nematode.
10. A method for inhibiting the growth of a microorganism which comprises contacting the microorganism or an environment containing the microorganism with an effective amount of one or more compounds or salts of claim 1 , wherein the microorganism is a bacterium, a fungus, an algae or a nematode.
11. The method of claim 10 , wherein the microorganism is a mycobacterium or a nematode.
12. A method of treating an infection by a microorganism having Uridine 5′-diphosphate (UDP)-galactopyranose mutase (UGM) in an individual in need of such treatment by administering to the individual an effective amount of one or more compounds of claim 1 , wherein the microorganism is a bacterium, a fungus, an algae or a nematode.
13. The method of claim 12 , wherein the infection is tuberculosis.
14. A compound of formula VA:
and salts thereof,
where:
Y is OH, or NHSO 2 R;
n and m are independently 0 or 1;
R is an optionally substituted C 1 -C 6 alkyl, an optionally substituted C 1 -C 6 alkenyl, an optionally substituted alkoxy, an optionally substituted thioalkyl, an optionally substituted carbocyclyl, or an optionally substituted heterocyclyl; and
R 11 and R 12 are selected from an optionally substituted carbocyclyl, or an optionally substituted heterocyclyl, wherein one of R 11 or R 12 is an optionally substituted biphenyl or an optionally substituted naphthyl; and
wherein optional substitution is substitution with one or more halogen, C 1 -C 3 alkyl, C 1 -C3 alkoxy, nitro, cyano, acyl, or halogenated C 1 -C 3 alkyl.
15. The compound or salt of claim 14 , wherein one of R 11 or R 12 is an substituted biphenyl or an unsubstituted naphthyl.
16. The compound or salt of claim 14 , wherein R 11 and R 12 are selected from optionally substituted phenyl, optionally substituted biphenyl, optionally substituted naphthyl or optionally substituted heteroaryl.
17. The compound or salt of claim 15 , wherein one of R 11 or R 12 is an optionally substituted biphenyl and the other of R 11 or R 12 is selected from furan-2-yl, furan-3-yl, thiophen-2-yl, thiophen-3-yl, 1-methylfuran-3-yl, 4-methylphenyl, 4-methoxyphenyl, 4-fluorophenyl, 4-bromophenyl, 4-chlorophenyl, or 4-iodophenyl.
18. The compound or salt of claim 14 , where R is selected from unsubstituted C 1 -C 3 alkyl, C 1 -C 3 haloalkyl, unsubstituted phenyl, phenyl substituted with one or more halogen, nitro substituted phenyl, thiophen-2-yl, halogenated thiophen-2-yl, thiophen-3-yl, halogenated thiophen-3-yl, imidazol-4-yl, imidazol-3-yl, imidazol-2-yl, and 1-alkyl imidazol-4-yl.
19. A pharmaceutically acceptable composition which comprises one or more compounds or salts of claim 14 and a pharmaceutically acceptable carrier.
20. A method for inhibiting Uridine 5′-diphosphate (UDP)-galactopyranose mutase (UGM) which comprises contacting UGM with an amount of one or more compounds or salts of claim 14 effective for inhibiting the enzyme.
21. A method for inhibiting the growth of a microorganism which comprises contacting the microorganism or an environment containing the microorganism with an effective amount of one or more compounds or salts of claim 14 , wherein the microorganism is a bacterium, a fungus, an algae or a nematode.
22. A method of treating an infection by a microorganism having Uridine 5′-diphosphate (UDP)-galactopyranose mutase (UGM) in an individual in need of such treatment by administering to the individual an effective amount of one or more compounds of claim 14 , wherein the microorganism is a bacterium, a fungus, an algae or a nematode.
23. The method of claim 22 , wherein the infection is tuberculosis.
24. The compound of claim 1 , having formula:
25. The compound of claim 24 , wherein R is selected from methyl, trifluoromethyl, phenyl, 4 nitrophenyl, 4-chlorophenyl and 2-nitrophenyl.
26. The method of claim 21 , wherein the microorganism is a bacterium.